Evidence map›Paper›PMID 35408749›Full record

ArticleMolecules (Basel, Switzerland)2022

Non-Peptide Opioids Differ in Effects on Mu-Opioid (MOP) and Serotonin 1A (5-HT

Vlad Radoi, Gerd Jakobsson, Vinko Palada, Andrej Nikosjkov, Henrik Druid, Lars Terenius, Eva Kosek, Vladana Vukojević

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. AI-derived therapeutic development of a serotonin receptor-targeting drug for the treatment of opioid use disorder.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Vlad RadoiDepartment of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden.ORCID 0000-0002-9657-8303
Gerd JakobssonDepartment of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, 587 58 Linköping, Sweden.ORCID 0000-0002-3249-3351
Vinko PaladaDepartment of Physiology, SleepWell Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland.
Andrej NikosjkovDepartment of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden.
Henrik DruidDepartment of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, 587 58 Linköping, Sweden.ORCID 0000-0002-9198-023X
Lars TereniusDepartment of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden.
Eva KosekDepartment of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden.
Vladana VukojevićDepartment of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden.
Karolinska Institutet · SESwedish National Board of Forensic Medicine · SEUniversity of Helsinki · FIUppsala University · SE

Funding

European Union Seventh Framework Programme (FP7/2007 - 2013) 602919Swedish Foundation for Strategic Research SBE13-0115Swedish Research Council 2016-01922Swedish Research Council 2018-05337
6 · The paper itself

Abstract

The importance of the dynamic interplay between the opioid and the serotonin neuromodulatory systems in chronic pain is well recognized. In this study, we investigated whether these two signalling pathways can be integrated at the single-cell level via direct interactions between the mu-opioid (MOP) and the serotonin 1A (5-HT1A) receptors. Using fluorescence cross-correlation spectroscopy (FCCS), a quantitative method with single-molecule sensitivity, we characterized in live cells MOP and 5-HT1A interactions and the effects of prolonged (18 h) exposure to selected non-peptide opioids: morphine, codeine, oxycodone and fentanyl, on the extent of these interactions. The results indicate that in the plasma membrane, MOP and 5-HT1A receptors form heterodimers that are characterized with an apparent dissociation constant Kdapp = (440 ± 70) nM). Prolonged exposure to all non-peptide opioids tested facilitated MOP and 5-HT1A heterodimerization and stabilized the heterodimer complexes, albeit to a different extent: Kd, Fentanylapp = (80 ± 70) nM), Kd,Morphineapp = (200 ± 70) nM, Kd, Codeineapp = (100 ± 70) nM and Kd, Oxycodoneapp = (200 ± 70) nM. The non-peptide opioids differed also in the extent to which they affected the mitogen-activated protein kinases (MAPKs) p38 and the extracellular signal-regulated kinase (Erk1/2), with morphine, codeine and fentanyl activating both pathways, whereas oxycodone activated p38 but not ERK1/2. Acute stimulation with different non-peptide opioids differently affected the intracellular Ca2+ levels and signalling dynamics. Hypothetically, targeting MOP−5-HT1A heterodimer formation could become a new strategy to counteract opioid induced hyperalgesia and help to preserve the analgesic effects of opioids in chronic pain.

Indexed as

Analgesics, OpioidChronic PainReceptors, Opioid, muCodeineFentanylHumansMAP Kinase Signaling SystemMorphineOxycodoneReceptor, Serotonin, 5-HT1AAnalgesics, OpioidCodeineFentanylMorphineOxycodoneReceptor, Serotonin, 5-HT1AReceptors, Opioid, muchronic painfluorescence cross-correlation spectroscopy (FCCS)G protein-coupled receptor (GPCR)opioidserotonin

Identifiers

PMID35408749
PMCPMC9000251
OpenAlexW4223481050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.